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INVESTIGATION

Doxorubicin-Induced Cardiotoxicity in Collaborative
Cross (CC) Mice Recapitulates Individual
Cardiotoxicity in Humans
Caroline J. Zeiss,*,1 Daniel M. Gatti,† Olga Toro-Salazar,‡ Crystal Davis,† Cathleen M. Lutz,†
Francis Spinale,§ Timothy Stearns,† Milena B. Furtado,† and Gary A. Churchill,†

*Yale University School of Medicine, New Haven, CT 06520, †The Jackson Laboratory, Bar Harbor, ME 04609,
‡Connecticut Children’s Medical Center, University of Connecticut School of Medicine, Hartford, CT 06106, and
§University of South Carolina School of Medicine, Columbia SC 29208
ORCID IDs: 0000-0003-1181-3544 (C.J.Z.); 0000-0001-9190-9284 (G.A.C.)

ABSTRACT Anthracyclines cause progressive cardiotoxicity whose ultimate severity is individual to the
patient. Genetic determinants contributing to this variation are difﬁcult to study using current mouse models.
Our objective was to determine whether a spectrum of anthracycline induced cardiac disease can be elicited
across 10 Collaborative Cross mouse strains given the same dose of doxorubicin. Mice from ten distinct strains
were given 5 mg/kg of doxorubicin intravenously once weekly for 5 weeks (total 25 mg/kg). Mice were killed at
acute or chronic timepoints. Body weight was assessed weekly, followed by terminal complete blood count,
pathology and a panel of biomarkers. Linear models were ﬁt to assess effects of treatment, sex, and sex-bytreatment interactions for each timepoint. Impaired growth and cardiac pathology occurred across all
strains. Severity of these varied by strain and sex, with greater severity in males. Cardiac troponin I and
myosin light chain 3 demonstrated strain- and sex-speciﬁc elevations in the acute phase with subsequent
decline despite ongoing progression of cardiac disease. Acute phase cardiac troponin I levels predicted
the ultimate severity of cardiac pathology poorly, whereas myosin light chain 3 levels predicted the
extent of chronic cardiac injury in males. Strain- and sex-dependent renal toxicity was evident.
Regenerative anemia manifested during the acute period. We conﬁrm that variable susceptibility to
doxorubicin-induced cardiotoxicity observed in humans can be modeled in a panel of CC strains. In
addition, we identiﬁed a potential predictive biomarker in males. CC strains provide reproducible
models to explore mechanisms contributing to individual susceptibility in humans.

The chemotherapeutic use of anthracyclines is limited by their capacity
to induce dose-dependent cardiotoxicity (Gianni et al. 2008), leading to
development of heart failure and death(Gianni et al. 2008; Toro-Salazar
et al. 2015). Efﬁcacy and toxicity of anthracycline agents is highly variable in humans, reﬂecting the genetic diversity of patient populations as
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well as gender differences (Franco et al. 2011; Lipshultz et al. 2015).
Multifactorial mechanisms including changes in cellular oxidative stress
and viability contribute to acute anthracycline-induced cardiotoxicity (AIC) (De Angelis et al. 2010; Simůnek et al. 2009; Semsei et al.
2012). Maladaptive cardiac remodeling, comprising myocyte hypertrophy and extracellular matrix alterations (including loss of normal
ﬁbrillar collagen architecture and interstitial ﬁbrosis) are associated with
chronic induced toxicity and development of heart failure (Bernaba
et al. 2010; Toro-Salazar et al. 2013; Adamcova et al. 2010). Anthracycline induced adverse cardiac remodeling is thought to be mediated
through inﬂammation and cytokine release in response to oxidative
stress (Bernaba et al. 2010).
Cardiac troponin elevation during chemotherapy is a useful tool in
risk stratiﬁcation for future cardiac injury (Bertinchant et al. 2003;
Cardinale et al. 2004) however, this protein is released in serum only
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after cardiac tissue damage has occurred. The purpose of this study is to
develop a suite of mouse models that model variable susceptibility to
cardiotoxicity in human patients. These can be used to interrogate the
mechanisms of AIC, and to identify early predictive biomarkers and
risk alleles. Current approaches to preclinical testing using animal
models aim to minimize variability by limiting genetic diversity. This
can yield preclinical ﬁndings biased by genetic background and impede
subsequent translation to more complex human systems. Genetically
diverse mice, such as the Collaborative Cross (CC) better recapitulate
the range of phenotypes seen in the human population compared to a
single inbred strain (Harrison et al. 2014; Collaborative Cross Consortium 2012). CC strains are recombinant inbred mice derived from eight
inbred founder strains (A/J, C57BL/6J, 129S1/SvImJ, NOD/ShiLtJ,
NZO/HlLtJ, CAST/EiJ, PWK/PhJ & WSB/EiJ) that encompass 90%
of the genetic diversity available in the laboratory mouse. CC strains
provide reproducible genetic backgrounds with ﬁxed inbred genotypes.
Since each CC strain is inbred, each represents a reproducible model
with some degree of susceptibility to AIC. Using 10 strains of CC mice,
we identify distinct strain and sex-speciﬁc susceptibility to AIC. Additionally, we correlate the severity of strain-speciﬁc AIC with serum
biomarker levels and assess the capacity of these to predict the extent
of eventual cardiac injury.
METHODS
Experimental animals and doxorubicin dosing
We obtained CC mice from the Jackson Laboratory from each of
the following strains: CC001/UncJ, CC010/GeniUncJ, CC011/UncJ,
CC019/TauUncJ, CC032/GeniUncJ, CC037/TauUncJ, CC040/TauUncJ,
CC041/TauUncJ, CC042/GeniUncJ, and CC051/TauUncJ. For brevity we
will drop the substrain designations below. Dose protocols based on a
previous juvenile model of doxorubicin-induced cardiac dysfunction
were applied(Zhu et al. 2008). 32 mice per CC strain equally split by
sex and treatment regimen (acute and chronic doxorubicin treatment
and control groups) were used. A total of 25 mg/kg of doxorubicin
(5 tail vein injections of 5 mg/kg in saline were given at 7-day
intervals beginning at 28 days (4 weeks) of age. Two time courses
for experimental endpoint were chosen; acute and chronic. Eight
dosed mice per CC strain (4 males and 4 females) were killed one
week after the ﬁnal doxorubicin injection to study acute cardiotoxicity (6 weeks; acute phase). A second cohort of dosed mice
(4 males and 4 females) per CC strain were killed 6 weeks after
the ﬁnal doxorubicin injection to study the chronic effects of the
drug (12 weeks; chronic phase). An equivalent number of control
mice (8 males and 8 females) per CC line were subjected to the
same experimental regimen, with the exception that they received
weekly injections of saline instead of doxorubicin (control). The
animals were observed daily for general health, and weighed
weekly throughout the course of the study. Animals were group
housed by sex in ventilated cages with corn-cob bedding. They
were placed on a 12:12 light:dark cycle, and provided regular ad
libidum chow and water. The Jackson Laboratory (Mount Desert
Island, ME) is an AAALAC accredited facility. All procedures were
performed in accordance with NIH regulations and approved by
the Jackson laboratory Institutional Animal Care and Use Committee under the number 15009. (Figure1)
Serum biomarker measurement
Blood samples were obtained for each animal at the end of 6 weeks (acute
phase) or 12 weeks (chronic phase). Following euthanasia by carbon
dioxide asphyxiation, animals were exsanguinated by cardiac puncture
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Figure 1 Study design. 10 CC strains were selected. 32 mice per line
equally split by sex and treatment regimen (acute and recovery
doxorubicin treatment and control groups) were used. A total of
25 mg/kg of DOX (5 tail injections of 5 mg/kg in saline were given at
7-day intervals beginning at 28 days of age. Two time courses for
experimental duration were chosen. Eight dosed mice per CC line
(4 males and 4 females) were killed one week after the ﬁnal doxorubicin
injection to study acute cardiotoxicity (acute phase). A second cohort of
dosed mice (4 males and 4 females) per CC strain were killed 6 weeks
after the ﬁnal DOX injection to study the chronic effects of the drug
(chronic or recovery phase). This regimen was duplicated for a similar
cohort of control mice, who received weekly injections of saline. Mice
were weighed weekly. At either 6 or 12 weeks, acute and chronic
cohorts were killed, blood taken for serum biomarkers and complete
blood count (CBC), and tissue collected for pathology.

and blood collected in serum separator tubes for cardiac troponin
I (cTNI), skeletal troponin I (sTNI), myosin light chain 3 (MYL3)
and fatty acid binding protein 3 (FABP1) measurement using the
Muscle Injury Panel kit from Meso Scale Discovery (MSD; Rockville,
MD) following the manufacturer’s instructions. Average values for
the lower limit of detection for each assay as provided by the manufacturer (https://www.mesoscale.com/en/products/muscle-injurypanel-3-mouse-kit-k15186c/) are as follows: cTNI (0.0088 ng/ml),
FABP3 (0.3 ng/ml), MYL3 (0.048 ng/ml) and sTNI (0.085 ng/ml).
50ml of undiluted serum was used per reaction.
Complete blood count
An aliquot of blood was collected in Microtainer tubes coated with
EDTA (BD Biosciences, Franklin Lakes, NJ) for measurement of white
blood cell count (WBC), platelets, red blood cell count (RBC), hemoglobin (Hb), hematocrit (HCT), mean corpuscular volume (MCV),
mean corpuscular hemoglobin (MCH) and mean corpuscular hemoglobin concentration (MCHC). Whole blood measurements were performed by the JAX Clinical Assessment Service using the Siemens Advia
120 hematology analyzer.
Gross necropsy and organ weights
Following euthanasia by carbon dioxide asphyxiation, the pluck was
removed, lungs intratracheally inﬂated with 10% neutral buffered
formalin, and the intact heart and lungs, as well as reproductive tract,
liver, spleen and right kidney immersed in 10% neutral buffered
formalin (NBF) for 7-10 days. Organ weights (kidneys, liver, spleen)
were recorded as a percentage of total body weight.

Histopathology and immunohistochemistry
All tissues underwent routine parafﬁn processing followed by sectioning
at 5 mm and staining with Hematoxylin and Eosin (H&E; Yale Mouse
Research Pathology Core in the Section of Comparative Medicine, Yale
School of Medicine; http:/mrp.yale.edu). Hearts were sectioned longitudinally to allow visualization of all four chambers. Using hematoxylin
and eosin (HE) stained sections, two sections of each heart were scored
semi-quantitatively for severity of cardiac injury (adapted from previously published methods (Desai et al. 2013; Desai et al. 2014; Reagan
et al. 2013) using three histologic variables. These were cytoplasmic
vacuolation, (Desai et al. 2014; Ferrans 1978) inﬁltration by mononuclear cells, (Desai et al. 2013) and interstitial ﬁbrosis with myoﬁber
disorganization/atrophy (Ferrans 1978). Each criterion was scored on
a 4-point scale with 0 representing normal histologic appearance and
3 representing the most severe score (see S1 Table 1 for scoring system).
The scale was applied to each of 5 anatomical regions (left and right
atrium, interventricular septum, left and right ventricular free wall).
Uncommon histologic ﬁndings (mineralization, atrial thrombosis,
perivascular lymphocytes) were recorded by region as absent (0) or
present (1). The scores for each anatomical region were summed to
obtain a total cardiac score for each animal. Two longitudinal renal
sections from the right kidney were examined for each animal. Semiquantitative renal scoring was achieved by recording the approximate
percentage per section occupied by a series of glomerular and tubular
changes (S1 Table 1). Scores for each change were summed to obtain a
composite score for each kidney. A similar approach was used to score
pulmonary pathology. Criteria for semi-quantitative scoring of cardiac,
renal and pulmonary lesions are given in S1 Table 1. Gonadal, liver and
splenic pathology was recorded as present or absent, and described
qualitatively only. The pathologist was blinded as to treatment status
and strain of each mouse.
The relationship between myoﬁber degeneration/atrophy, interstitial ﬁbrosis and mononuclear cell inﬁltration was explored by supplementing H&E staining with reticulin staining to reveal changes in the
reticulin (Type III collagen) framework surrounding myoﬁbers, Sirius Red staining (for Type II collagen), and immunohistochemical
detection of macrophages (Iba-1; ab107159, 1:100, Abcam, Cambridge,
MA), myoﬁbroblasts (alpha smooth muscle actin; SMA; ms113,1:1500,
Neomarkers, Fremont, CA), matrix metalloproteinase 2 (MMP-2;
1:100, 6E3F8, ab86607, Abcam, Cambridge, MA) and cleaved caspase-3 (NB100-56113, 1: 1000, Novus Biologicals, Littleton, CO).

Animal survival and changes in body weight
One control animal in the chronic cardiotoxicity group died prior to
completion of the study period. 7 animals across both sexes in the acute
treatment group died prematurely (strains CC001, CC 032, CC 042,
CC 024, CC 040). 17 animals in the chronic cardiotoxicity group died.
Deaths occurred across both sexes and in 7/10 strains (CC 001, CC 032,
CC 042, CC 024, CC 019, CC 010, CC 040), but were clearly overrepresented in one strain (CC 040). CC 040 was a very susceptible strain,
with most animals dying by the end of 12 weeks. A similar trend was seen
for females of CC 019 and CC 042. Consistent with previously reported
data across animal species (Bertinchant et al. 2003; Desai et al. 2013;
Manno et al. 2016), doxororubicin -treated animals demonstrated
impaired growth over time compared to age matched vehicle treated
controls. This varied by strain and sex. Signiﬁcant differences in individual organ weights were noted in four instances (data not shown),
but no pattern was identiﬁed. (Figure 2)

Statistical analysis
i) Body/organ weight: After batch normalization (Johnson et al. 2007),
we ﬁt linear models to assess effects of treatment, sex, and sex-bytreatment interaction for each timepoint (acute or chronic). Linear
models utilize the statistical method of linear regression to describe
the relationship between a dependent variable y (or response) as a
function of one or more independent variables Xi (or predictors).
Generalized linear mixed models include random effects that allow
modeling of correlated data that may be non-normally distributed.
This allows evaluation of the extent to which interaction between
independent variables affects the response. Data were transformed
as log(x+c), where the offset constant c was determined by visual
inspection of quantile plots to best approximate a normal distribution (Berry 1987). ii) Cardiac and renal scoring: Log(y + 10) transformed raw data were used to ﬁt a linear model that examined the
main effects of treatment, sex and timepoint (acute or chronic) with
two additional terms examining interactions of treatment with sex
and timepoint. iii) Serum biomarkers: Following batch normalization,
various transformations were used for cTNI [log(x + 0.001)], FABP3

Cardiac disease scoring
Scores for each anatomical region were summed to obtain a total cardiac
score for each animal. Lesions occurred in all compartments of the heart,
with higher scores indicating increasing severity across all anatomical
locations. Cardiac severity scores were higher in the majority of doxorubicin-treated animals (Figure 3). These treatment effects reached
statistical signiﬁcance in 6 strains (CC011, CC019, CC032, CC040,
CC042, CC051) (Table 1). In CC011, signiﬁcance was driven by consistently low scores in controls, as scores in treated animals were
relatively low at both time points. Thus we did not consider CC011
to be a strain with a strong adverse treatment effect. More severe cardiac
pathology was noted in most chronically treated animals, timepoint
(acute vs. chronic) was statistically signiﬁcant for strain CC032, and
the interaction of treatment with timepoint was signiﬁcant in four
strains (CC001, CC019, CC041, CC042). Susceptibility to doxorubicin-induced cardiac injury varied by sex with greater injury occurring
in either males (CC010, CC037, CC041) or in females (CC001). No
strain was immune to some degree of cardiac damage, however varying
strain susceptibility to cardiac toxicity induced by doxorubicin could be

[log(x)], MYL3 [log(x + 0.01)], and for sTNI [log(x + 0.1)]. Results were
reported as estimates (standard error) with Benjamini-Hochberg adjusted p-values. For each strain, a mixed-effects model with sex, treatment, timepoint, sex by treatment and treatment by timepoint as
ﬁxed effects and mouse as a random effect was used. This approach
was chosen as both acute and chronic measurements for some mice
were available, and only acute measurements for others within a
strain. To assess whether cTNI and MYL3 levels in the acute phase
predict the ultimate extent of cardiac injury (as quantiﬁed by cardiac
scores in the chronic timepoint), a linear model was applied to each
sex. Only mice that survived to the chronic timepoint with provided
cTNI or MYL3 measurements during the acute timepoint were included (65 data points, 29 female and 36 males).
Data access and analysis
Supplemental ﬁles include S1 Table 1 (semi-quantitative histologic
scoring systems), renal pathology and severity scoring (S2 Table 2
and S1 Figure 1), biomarker data for cardiac troponin I, myosin light
chain 3, fatty acid binding protein 3 and serum troponin 1 (S3 Table 3,
S4 Table), extra-cardiac histopathology (S2 Figure 2) and hematologic
data (S3 Figure 3). Supplemental material available at FigShare: https://
doi.org/10.25387/g3.8284058.
RESULTS
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Figure 2 Body weight. Means and
standard error at each weekly time
point are shown for each strain, with
a vertical gray line delineating acute
(6 weeks) and chronic (12 week) time
points. Females are shown on the
top panel and males beneath. Doxorubicin-treated animals (red) all demonstrate impaired growth over time
compared to age matched vehicle
treated controls (blue). Signiﬁcant
p values (,0.05) for treatment effect
(black asterisk), or treatment sex interaction (white asterisk) at acute or
chronic timepoints are shown (asterisks are placed on either side of the
vertical gray line to indicate signiﬁcance at either acute or chronic timepoints). CC 40 was a very susceptible strain, with all most animals dying by the end of 12 weeks. A similar trend
is seen for females of CC 19 and CC 42.

discerned. Overall, three strains appeared relatively resistant to chronic
cardiac injury (CC011, CC037 and CC051), with all remaining strains
experiencing chronic injury, most severe in CC019 and CC032, CC041
and CC042 (note that most animals in CC040 had died by the chronic
stage, and are absent from the analysis). These animals had high renal
scores in the acute stage and are likely to have died from combined
cardiac and renal toxicity – pathology was not available. Rare vehicle
treated animals experienced myoﬁber vacuolation, disintegration and
focal ﬁbrosis - these clustered by strain and were considered a manifestation of mild strain-speciﬁc cardiac pathology unrelated to doxorubicin exposure (CC001, CC019, CC041).
Qualitative cardiac pathology
Acutely intoxicated hearts experienced subtle changes characterized
primarily by intracytoplasmic myoﬁber vacuolation typical of doxorubicin toxicity (Figure 4). Additional changes included disintegration
of individual myoﬁbers, aggregation of small numbers of macrophages

(Figure 5), or regions of subtle disorganization characterized by subjective individual myoﬁber atrophy. These changes were randomly
scattered through the myocardium, but noted most commonly in ventricles and interventricular septum. Atrial pathology was similar in
nature, and could be locally more severe in individual animals, with
atrial thrombosis (Figure 4), myoﬁber loss and ﬁbrosis, macrophage
and myoﬁbroblast inﬁltration (Figure 5). Pathology in chronically
intoxicated hearts was generally more extensive. The prevailing
pattern was one of myoﬁber disorganization, marked variation in
myoﬁber diameter and ﬁne chicken-wire like interstitial ﬁbrosis
(Figure 4, Figure 6). Intracytoplasmic vacuolation did not prevail,
but was still evident in some animals. Rarely, focal regions of myoﬁber
loss and frank replacement ﬁbrosis were noted (Figure 5). This pattern was more common in atria and was accompanied by scattered
macrophage inﬁltration and myoﬁbroblast proliferation consistent
with ﬁbroplasia (Figure 5)(Zhao et al. 2015). In chronically intoxicated animals, histologic abnormalities were often very severe in atria,

Figure 3 Overview of cardiac scores
across all 10 CC lines. Means and
standard error at each weekly time
point are shown for each strain, with
a vertical gray line delineating acute
(A; 6 weeks) and chronic (C; 12 week)
time points. Females are shown on
the top panel and males beneath.
The majority of doxorubicin-treated
animals (red) demonstrate cardiac
injury (increased scores) over time
compared to age matched vehicle
treated controls (blue). Strains with
p values ,0.05 for treatment effect,
treatmentsex, and treatmenttimepoint
interactions are indicated with black,
gray and white asterisks respectively (located above each strain name). Red
and blue rectangles indicate those
strains in which both sexes exhibit
marked doxorubicin susceptibility or
resistance respectively. Strain 40 is
very susceptible, with most doxorubicin-treated animals dying before the
end of the study.
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n Table 1 Statistical analysis of semi-quantitative cardiac scoring
Strain
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC

01
10
11
19
32
37
40
41
42
51

Treatment
0.076
0.067
0.072
0.138
0.172
20.003
0.136
0.006
0.094
0.103

(0.041)
(0.031)
(0.02) 
(0.025) 
(0.025) 
(0.028)
(0.04) 
(0.031)
(0.032) 
(0.033) 

Sex
20.034
20.031
20.039
20.028
20.029
20.022
0.03
20.069
20.007
20.022

(0.034)
(0.026)
(0.016)
(0.02)
(0.021)
(0.023)
(0.033)
(0.03)
(0.024)
(0.027)

Time
20.045
0.052
0.009
0.034
0.112
0.036
20.01
0.019
20.018
0.015

(0.034)
(0.027)
(0.016)
(0.02)
(0.021)
(0.023)
(0.033)
(0.03)
(0.024)
(0.027)

Sex X Trt
20.019
0.099
0.024
0.015
20.038
0.114
0.033
0.178
0.009
0.024



(0.048)
(0.036)
(0.023)
(0.028)
(0.029)
(0.031)
(0.052)
(0.039)
(0.036)
(0.037)

Trt X timepoint





0.14
0.021
0.021
0.075
20.01
0.038
0.153
0.097
0.131
20.028

(0.048)
(0.037)
(0.023)
(0.029)
(0.029)
(0.031)
(0.061)
(0.039)
(0.036)
(0.037)








Linear model examining main effects (sex, treatment;Trt and time) and two additional treatment interactions (with sex and time). All values are given as estimates
(standard error). Benjamini-Hochberg adjusted p-values are indicated as asterisks.
P , 0.05.
P , 0.01.
P , 0.001.
CC040†: all but two animals in the chronic group died prematurely.

where they were often accompanied by lymphoplasmacytic and histiocytic inﬂammation, myoﬁber loss, focal scarring and atrial thrombosis. As noted in other doxorubicin toxicity studies (Kobayashi et al.
2016; Toya et al. 2014), macrophage and myoﬁbroblast inﬁltration
were far less prominent in areas of diffuse myoﬁber disorganization and
ﬁne ﬁbrosis (Figure 6) - in these areas, SMA expression was increased in
myoﬁber cytoplasm, consistent with pathological re-expression fetal
markers (Szibor et al. 2014). Rare individual myoﬁbers expressed
Mmp2, most commonly in the chronic phase (Figure 5). Myoﬁbers
immunopositive for cleaved caspase-3 were uncommon, even during
the acute phase (Figure 5).
Extracardiac pathology
Renal toxicity was noted in several strains. Renal severity scores tended to
be higher in the majority of doxorubicin-treated animals (S1 Figure 1),
with signiﬁcance treatment effects seen in 3 strains (CC011, CC019,
CC040) (S2 Table 2). All of these strains also experienced signiﬁcant
cardiotoxicity. Susceptibility to doxorubicin-induced renal injury varied
by sex with greater injury occurring in males (CC001, CC037, CC040,

CC042). Of these strains, a similar male susceptibility to cardiotoxicity
was noted in CC037. Qualitatively, the least severe and most common
renal changes were characterized by increased glomerular cellularity.
More severe changes involved glomeruli (increased mesangial matrix,
segmental tuft atrophy or diffuse glomerulosclerosis), tubules (focal
tubular basophilia, tubular loss, atrophy and dilation) and interstitium
(ﬁbrosis and mononuclear inﬂammation; S2 Figure 2). Splenic changes
ranged from expansion of red pulp with marked extramedullary hematopoeisis to complete red pulp collapse in both acute and recovery
treatment groups (S2 Figure 2). White pulp remained intact, consistent
with relatively unchanged lymphocyte counts.
Doxorubicin treatment in males was invariably associated with
severe testicular degeneration. Untreated males of some strains experienced mild testicular degeneration of a similar nature, consistent with
previously reported strain-dependent testicular pathology (CC001,
CC032, CC051, CC010)(Shorter et al. 2017).
Pulmonary pathology consistent with heart failure was evident in only
one strain (CC040) in recovery phase animals with very high cardiac
scores. Striking pulmonary vascular pathology (intense perivascular

Figure 4 Cardiac histopathology in animals 6 weeks
(acute) and 12 weeks (chronic) after initiating doxorubicin (Dox) treatment (25mg/kg total cumulative dose,
acute). Intracytoplasmic vacuolation typical of doxorubicin toxicity (black arrows, A and inset), accompanied
by rare myoﬁber atrophy (white arrow, A) prevailed in
acutely intoxicated mice. In the chronic phase (B),
pathology was dominated by areas of disorganization
with marked variation in myoﬁber diameter, myoﬁber
vacuolation in some animals (black arrows), and ﬁne
chicken-wire like ﬁbrosis (white arrows, C and inset, Sirius
Red). Atrial pathology was accompanied in some cases
by atrial thrombosis (C). Atrial lesions were characterized
by myoﬁber vacuolation (white arrows, D), myoﬁber
atrophy/loss, and lymphohistiocytic inﬂammation (black
arrows, D). Atrial lesions (illustrated in an acute phase
animal in C) were more severe in the chronic phase.
Hematoxylin and eosin (A, D); Sirius Red staining (inset,
B). Bar = 50mm (A, B, inset B, D); 20mm (inset A);
200 mm (C).
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Figure 5 Pathology in DOX treated acute and
recovery phase mice. Regions of myoﬁber loss
and frank replacement ﬁbrosis were noted,
most commonly in atria (A, acute phase), and
rarely in ventricles (D, recovery phase). These
areas were accompanied by macrophage inﬁltration (B, E) and myoﬁbroblast proliferation
(C) consistent with ﬁbroplasia. Rare myoﬁbers
were matrix metalloproteinase 2 (F, recovery
phase animal) or caspase-3 positive (G, acute
phase animal). Reticulin staining (A, D); Immunohistochemistry: Iba 1(B, E; macrophages),
alpha SMA (C), MMP-2 (F) and cleaved caspase -3 (G) Bar = 100mm (A-C); 50mm (D-F);
20mm (G).

mixed inﬂammation with marked endothelial proliferation) was
noted in untreated mice of one strain (CC032) consistent with
strain–associated pathology unrelated to doxorubicin treatment.
Serum biomarkers
Alteration in serum cardiac troponin I (cTNI), myosin light chain
3 (MYL3), fatty acid binding protein 3 and serum troponin 1 in acute
and chronic phases were evaluated (S3 Table 3). Only cTNI (pg/ml) and
MYL3 (pg/ml) exhibited signiﬁcant treatment effects across multiple
strains (Figure 7 and S4 Table 4). Both cTNI and MYL3 tended to
decrease between acute and chronic phases, in contrast to cardiac scores
which increased over time. These data indicate that serum levels of
these biomarkers are highest during acute cardiac injury, and decline
during the chronic phase, despite ongoing or worsening of cardiac
injury. The exception to this was strain CC 37, in which cTNI and
MYL3 levels increased over time. cTNI exhibited a signiﬁcant treatment effect in almost all strains, compared to a similar ﬁnding in 5/10
strains for MYL3, indicating that cTNI is the more sensitive indicator of
acute cardiac injury. We employed a linear model based test to assess
whether troponin levels in the acute phase predict the ultimate extent
of cardiac injury (as quantiﬁed by cardiac scores in the chronic
timepoint). We evaluated each sex separately to allow for potential
sex-speciﬁc differences. The signiﬁcance for cTNI was quite low
(P = 0.42 and P = 0.30 for females and males, respectively) indicating
that cTNI values in the acute phase do not reliably predict the

ultimate extent of cardiac injury. When MYL3 is combined with
cTNI, the predictive power remained poor for both biomarkers in
females (P = 0.14 and P = 0.13 for cTNI and MYL3, respectively).
However in males, MYL3 appeared to be predictive for extent of
ultimate cardiac injury in the chronic phase (P = 0.15 and P = 0.94
for cTNI and MYL3, respectively).
Hematologic change
While doxorubicin did not greatly affect white blood cell counts, it had
a strong effect on red blood cell counts (RBC). The most consistent
hematologic change was anemia that manifested during the acute period
(S3 Figure 3). Anemia was regenerative and had recovered in the chronic
phase. RBC decreased at the acute time point in almost all strains, except
CC051. Most strains recovered by the chronic time point, but some
strains (CC001, CC011, CC042) still had decreased RBC. Anemia was
accompanied by increased red blood cell distribution width (RDW) in all
strains at the acute time point, indicative of a regenerative response, and
consistent with extramedullary hematopoeisis noted histologically.
Most strains had recovered by the chronic time point, except for
CC032 and CC042. Platelets increased at the acute time point across
gender (CC011, CC040), or sex-speciﬁcally (CC001, CC019, CC032,
CC042). Most strains had recovered by the chronic time point. Doxorubicin did not cause myelosuppression at either the acute (orange) or
chronic (blue) time points, and white blood cell (WBC) counts were
altered in varying patterns. Many strains (CC010, CC040, CC041)

Figure 6 Diffuse interstitial cardiac ﬁbrosis in doxorubicin treated chronic
phase mice (left ventricle, A-C) compared to vehicle treated control mice
(D-F) at a similar location. Reticulin
stains (A) revealed myoﬁber disorganization, variation in myoﬁber diameter and ﬁne interstitial ﬁbrosis. This was
accompanied by minimal macrophage
inﬁltration (B) and myoﬁbroblast inﬁltration (C). Instead, SMA expression
was increased in myoﬁber cytoplasm
(C, inset). Reticulin staining (A, D);
Immunohistochemistry: Iba 1(B, E;
macrophages), alpha SMA (C, F).
Bar = 100mm (A-F); 20mm (inset, C).
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Figure 7 Overview of cTNI and MYL3
levels across all 10 CC strains. Means
and standard error at each weekly
time point are shown for each strain,
with a vertical gray line delineating
acute (A; 6 weeks) and chronic (C;
12 week) time points. Females are
shown on the top panel and males
beneath. The majority of doxorubicintreated animals (red) demonstrate cardiac injury (increased scores) over time
compared to age matched vehicle
treated controls (blue). Strains with
p values ,0.05 for treatment effect
are indicated with black asterisks.
Additional signiﬁcant treatmentsex,
and treatmenttimepoint interactions
are shown in Supplementary Tables 3
and 4.

showed increased neutrophil counts at the acute time point. This
increase persisted at the chronic time point in some strains (CC010,
CC032, CC041).
DISCUSSION
Our approach in this study was to utilize cardiac scoring as the primary
outcome measure of cardiac injury, and to assess the capacity of biomarker scores to accurately predict the extent of cardiac injury. Accompanying changes in body weight, extracardiac pathology and
hematologic responses were secondary measures. We demonstrated
clear strain-dependent variation in cardiac (and renal) susceptibility to
doxorubicin induced toxicity. All strains experienced some degree of
cardiac injury –this invariably worsened over time in the chronic group
despite cessation of doxorubicin treatment by the end of week 6. Extremes of clear high (CC019, CC032 and CC040) and low (CC011 and
CC051) susceptibility across both sexes were identiﬁed in ﬁve strains. In
remaining strains, sex-dependent variations in susceptibility were present. Consistent with previous reports(Jenkins et al. 2016), males were
more severely affected in most strains (CC010, CC019, CC041, CC042,
CC051) with females being more severely affected in only one strain
(CC001).
All anatomical regions of the heart were histologically affected –
lesions were typically scattered and quite rare in the acute phase of the
disease. Myoﬁber vacuolation characteristic of anthracycline toxicity
dominated acute cardiac histopathology, however, subtle myoﬁber disorganization and atrophy presaging later architectural distortion could
already be appreciated at this stage(Ferrans 1978). Cleaved caspase-3
positive myoﬁbers were present in the acute phase, however these
were rare (0-5/section), indicating that extensive activation of terminal
apoptotic pathways was minimal, or alternatively, was short-lived, or
accompanied by necrotic forms of cell death (Zhang et al. 2016). In

chronic phase animals, two patterns of cardiac ﬁbrosis were identiﬁed.
By far the most common was ﬁne chicken-wire like interstitial ﬁbrosis
(containing Sirius red positive Type 1 collagen) accompanied by pervasive myoﬁber atrophy and disorganization (most easily appreciable
using reticulin stains). Signiﬁcant inﬁltration of macrophages (Iba-1)
and myoﬁbroblasts (alpha-SMA) was not seen in these areas. Additionally, myoﬁber cytoplasm in ﬁbrotic regions was strongly alphaSMA immunoreactive, indicating regression to a fetal phenotype
(Szibor et al. 2014), and raising the possibility that myoﬁbers themselves contribute to pathologic extracellular matrix remodeling
through an aberrant transcriptional program (Bowers et al. 2010).
This notion is underscored by expression of Mmp-2 in myoﬁbers,
thus implicating these in collagen remodeling. Interstitial and perivascular deposition of collagen is characteristic of late stages of
cardiotoxicity and has been identiﬁed in subjects with AIC undergoing cardiac transplantation (Bernaba et al. 2010). A second pattern of ﬁbrosis characterized by focal marked myoﬁber loss,
replacement ﬁbrosis (discrete scarring) and dense inﬁltration by
macrophages and myoﬁbroblasts was evident. This was rare in ventricular wall and much more common in atria. Severity of atrial
lesions was marked in chronic phase animals, and quite commonly
associated with lymphocytic inﬂammation and atrial thrombosis.
The latter is a previously noted lesion in murine (but not human)
doxorubicin toxicity(Fujihira et al. 1993).
cTNI is considered a myocardium-speciﬁc biomarker, whereas
MYL3 is present in both cardiac and skeletal muscle (Tonomura
et al. 2012). Regardless, both were generally elevated in treated acute
phase animals, and declined over time in chronic phase mice of all
strains except one (CC 037). These results suggest that myoﬁbers are
injured by direct cardiotoxicity during periods of doxorubicin administration, but that different mechanisms contribute to adverse cardiac
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remodeling with development of progressive microscopic ﬁbrosis during the chronic phase. Previous studies have demonstrated that AIC is
mediated in part by an effect on the collagen matrix with loss of extracellular matrix and increase in ﬁbrosis(Bernaba et al. 2010; Caulﬁeld
and Bittner 1988; Toro-Salazar et al. 2013). Activation of matrix
metalloproteases (MMPs) and decreased levels of tissue inhibitors of
MMPs (TIMPs)(Kong et al. 2014) and inﬂammatory mediators play an
important role in LV remodeling. Myocyte hypertrophy (Spinale and
Zile 2013; Spinale 2002; Yokoyama et al. 1997), myosin heavy-chain
switch(Kubota et al. 1997), cardiac myocyte apoptosis (Krown et al.
1996) and extracellular matrix alterations with early loss of ﬁbrillar
collagen followed by late microscopic ﬁbrosis, contribute to adverse
cardiac remodeling ultimately leading to heart failure (Liew and Dzau
2004; Kong et al. 2014). In our pediatric early AIC cohort, we have
identiﬁed biomarker signatures in inﬂammatory, structural and cell
growth/viability pathways (Toro-Salazar et al. 2018). cTNI and
MYL3 exhibited signiﬁcant treatment effects across 9 and 5 strains
respectively, suggesting that cTNI was the more sensitive indicator of
acute injury. In agreement with previous reports (Cardinale et al. 2004;
Bertinchant et al. 2003; Reagan et al. 2013), cTNI elevation in the acute
phase was not predictive of the eventual extent of cardiac injury as
assessed by cardiac score in either sex (Armenian et al. 2014;
Moazeni et al. 2017). MYL3 was similarly non-predictive in females,
however in males, MYL3 levels in the acute phase were correlated
with the extent of eventual cardiac injury, implicating a sex-speciﬁc
use for this biomarker. The latter ﬁnding should be interpreted with
caution – MYL3 is not cardiac-speciﬁc, and in rodents, its clearance can
be inﬂuenced by renal toxicity(Tonomura et al. 2012).
Both carbon dioxide euthanasia and cardiac puncture could conceivably alter troponin levels in our cohort (Marquardt et al. 2018;
Everds 2017), however the of cardiac troponins to accurately predict
the extent of chronic cardiac injury remains an imperfect science. cTNI
is utilized in clinical practice (Horacek et al. 2008; Jones et al. 2017;
Simões et al. 2018; Ma et al. 2019). Cardiac troponin T has been used to
monitor anthracycline induced injury in clinical patients (Blaes et al.
2015; Bisoc et al. 2019), although its elevation following anthracycline
treatment is not invariable (Horacek et al. 2008; Lipshultz et al. 2004).
Both cTNI and cTNT are more reliable indicators of injury immediately following anthracycline exposure (Simões R et al., 2018). Assessing the capacity of cTNT to predict the extent of chronic cardiac injury
would be a useful addition in subsequent studies using murine model
systems(Jenkins et al. 2016). Future studies in susceptible and resistant
CC strains will help deﬁne regulatory molecular pathways related to
AIC predictors in these genetic variants.
Marked renal toxicity was evident in some strains. Lesions recapitulated previously described pathology centered on glomeruli (Yasuda
et al. 2010) with eventual extension to tubular and interstitial components. In general, renal toxicity was less prevalent than cardiotoxicity.
In contrast to cardiac pathology, overall worsening of renal pathology
over time was not nearly as marked. While some strains developed both
cardiac and renal injury across both sexes (CC019, CC040), others
exhibited relatively greater renal toxicity (CC051) indicating that some
genetic determinants of these two organ responses are shared, whereas
others are independently inherited. Like cardiotoxicity, susceptibility to
renal toxicity varied across strain, sex and timepoint. Renal toxicity is
well-described in rodents (Lee and Harris 2011) and pigs (Manno et al.
2016), but is less common in humans (Bárdi et al. 2007). The potential
of this lesion to affect biomarker clearance in mice (Tonomura et al.
2012), and thus confound translation of biomarker data from mice to
humans should not be underestimated. As in other species,(Manno
et al. 2016) severe testicular degeneration occurred in all treated males,

2644 |

C. J. Zeiss et al.

making this lesion the most consistent of all organ responses. Ovarian
atrophy was noted in some treated females, however this organ was not
available in sufﬁcient sections to adequately assess strain susceptibility
of this response.
Doxorubicin treatment generally impeded the rate of weight gain
across strains, however the extent of this could not be clearly correlated
with the extent of cardiac injury. Because humans receiving doxorubicin
have the added variable of neoplasia, and because their weight is very
individual, body weight was not considered a translationally useful
biomarker. Bone marrow suppression is commonly a dose limiting
toxic effect during active doxorubicin treatment in humans (Panis et al.
2012), dogs (Ahaus et al. 2000) and pigs (Manno et al. 2016) . This
effect can manifest across erythroid, granulocytic and thrombocytic
lineages (Panis et al. 2012). We did not observe myelosuppression in
our mice. Consistent with previous reports in mice (Desai et al. 2013),
the most profound hematologic abnormality was anemia during the
acute phase. This was regenerative, and red cell counts had normalized
by the chronic phase. Marked splenic extramedullary hematopoeisis
followed by eventual red pup exhaustion was noted in many doxorubicin treated mice, consistent with marked splenic hematopoeitic compensation for bone marrow toxicity. In contrast to humans, in which
splenic extramedullary hematopoiesis is negligible, the adult murine
spleen (and to lesser extent the liver) are capable of profound extramedullary hematopoiesis when stimulated (Sonoda and Sasaki 2012).
In this study, a spectrum of cardiac pathology could be demonstrated
that exhibited a wide range across strains, but was consistent within
strain. Resistant and susceptible strains provide a powerful tool to
investigate pathophysiologic mechanisms driving cardiac injury, particularly those that follow acute intoxication to create chronic ongoing
injury. These strains are similarly useful in the search for early stage
biomarkers that can be used to predict the extent of chronic injury.
Because mice within each CC strain are virtually genetically identical
(over 90% homozygous), CC mice are most ideally suited to identiﬁcation of reproducible anthracycline sensitive and resistant phenotypes.
These can be used to interrogate cellular mechanisms of AIC, particularly those underlying progressive interstitial ﬁbrosis, and to identify
early predictive biomarkers. For the identiﬁcation of genetic determinants contributing to AIC, genetically heterozygous mice generated
from the same 8 parental strains, i.e., the Diversity Outbred (DO) mice,
are better suited.
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